Anthera Pharmaceuticals Inc. (ANTH)

Company Description

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious illnesses, including cardiovascular and autoimmune diseases. Clinical-stage program includes a Phase 2, blisibimod study. Blisibimod targets elevated levels of B-lymphocyte stimulator, or BLyS (also known as BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sjögren’s Syndrome, Graves’ Disease and others.

COMPANY ADDRESS
25801 Industrial Blvd.
Suite B
Hayward, CA 94545
United States

COMPANY PHONE
510-856-5600

COMPANY WEBSITE



Get BioInvest's perspective on Anthera's CEO


Latest Company News

The Dirty Secret to Trading Danaher Corporation (DHR), Anthera Pharmaceuticals ... USA Commerce Daily - 11 hours ago Shares of Danaher Corporation (NYSE:DHR) are on a recovery track as they have regained 23.72% since bottoming out at $75.71 on Oct. 17, 2016. Anthera Pharmaceuticals, Inc. (ANTH) Recent Ownership Changes - Post Analyst Stock Profit Analysis: Anthera Pharmaceuticals, Inc. (ANTH) - The Oracle Examiner [...]
Fri, Mar 24, 2017 2:55:00 PM, Continue reading at the source
Anthera Pharmaceuticals, Inc. (ANTH) Insider Ownership stands at 12.46 The Newburgh Press - Mar 23, 2017 Considering the performance, Anthera Pharmaceuticals, Inc. (ANTH)'s shares have the potential to reach a high EPS of -0.17 per share, and a low EPS of -0.36 per share in the current quarter. [...]
Thu, Mar 23, 2017 1:00:00 PM, Continue reading at the source
Is It Time to go for Avon Products, Inc. (AVP), Anthera Pharmaceuticals, Inc ... StockNewsJournal - Mar 23, 2017 Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH), maintained return on investment for the last twelve months at -211.50, higher than what Reuters data shows regarding industry's average. [...]
Thu, Mar 23, 2017 11:37:00 AM, Continue reading at the source
Anthera Pharmaceuticals Inc. (ANTH) Settles Into New 52-Week Low on March 22 ... Equities.com - Mar 22, 2017 Shares of Anthera Pharmaceuticals Inc. (ANTH) sank into a new 52-week low yesterday, and could be a company to watch at the open. [...]
Wed, Mar 22, 2017 9:30:00 PM, Continue reading at the source
How Does Anthera Pharmaceuticals, Inc. (ANTH) Stack Up Right Now? StockNewsJournal - Mar 22, 2017 Anthera Pharmaceuticals, Inc. (ANTH) is an interesting player in the Healthcare space, with a focus on Biotechnology. [...]
Wed, Mar 22, 2017 5:14:00 PM, Continue reading at the source
Anthera Pharmaceuticals Inc. (ANTH) Moves Higher on Volume Spike for March 16 Equities.com - Mar 16, 2017 Anthera Pharmaceuticals Inc. (ANTH) traded on unusually high volume on Mar. 16, as the stock gained 1.43% to close at $0.41. ANTHERA PHARMACEUTICALS,INC. (NASDAQ:ANTH) Files An 8-K Entry into a Material ... - Market Exclusive Stock Showing Surging Activity: Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) - HugoPress [...]
Thu, Mar 16, 2017 9:30:00 PM, Continue reading at the source
Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock and ... GlobeNewswire (press release) - Mar 13, 2017 HAYWARD, Calif., March 13, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) (the “Company”) today announced that it intends to offer and sell shares of its common stock and warrants to purchase shares of its common stock in an ... [...]
Mon, Mar 13, 2017 7:52:00 PM, Continue reading at the source
ANTHERA PHARMACEUTICALS, INC. (NASDAQ:ANTH) Files An 8-K Results of Operations ... Market Exclusive - Feb 27, 2017 Anthera Pharmaceuticals, Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. Research Reports Coverage on Biotech Stocks -- Anthera Pharma, Arrowhead ... - PR Newswire (press release) [...]
Mon, Feb 27, 2017 11:56:00 PM, Continue reading at the source
IMPORTANT ANTHERA PHARMACEUTICALS, INC. INVESTOR ALERT: Wolf Haldenstein Adler ... GlobeNewswire (press release) - Feb 24, 2017 INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of purchasers of Anthera Pharmaceuticals, Inc. [...]
Fri, Feb 24, 2017 11:02:00 PM, Continue reading at the source
Anthera Pharmaceuticals Inc (NASDAQ:ANTH): Ignore The Lawsuits Insider Financial - Feb 23, 2017 Levi & Korsinsky, Lifshitz & Miller, Bronstein, Gewirtz & Grossman, Johnson & Weaver - just some of the LLPs flooding the PR streams for Anthera Pharmaceuticals Inc (NASDAQ:ANTH) at the major financial news outlets. Every one of these companies claims ... Anthera Pharmaceuticals Inc. (ANTH) Moves Lower on Volume Spike for February 23 - Equities.com Hot Stock for Investors: Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) - HugoPress [...]
Thu, Feb 23, 2017 1:52:00 PM, Continue reading at the source